CI vs INCY: fair value comparison
The Cigna Group and Incyte Corporation · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, CI currently sits closer to the top of our discount ranking. INCY carries the stronger quality grade. INCY carries the stronger momentum grade.
| CI | INCY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $278.88 | $124.37 |
| 12-month range | $244.41–$299.21 | $85.98–$119.52 |
| Sector rank | #32 of 113 Healthcare | #35 of 113 Healthcare |
| Quality grade | F | A |
| Momentum grade | D | A |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Fairly Valued | Overvalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: CI fair value analysis · INCY fair value analysis